MK-927 - A TOPICAL CARBONIC-ANHYDRASE INHIBITOR - DOSE-RESPONSE AND DURATION OF ACTION

被引:22
作者
HIGGINBOTHAM, EJ
KASS, MA
LIPPA, EA
BATENHORST, RL
PANEBIANCO, DL
WILENSKY, JT
机构
[1] WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL,ST LOUIS,MO 63110
[2] MERCK SHARP & DOHME LTD,CLIN RES & BIOSTAT,W POINT,PA 19486
关键词
D O I
10.1001/archopht.1990.01070030071031
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a two-center, double-masked, randomized, placebo-controlled, four-period crossover study. MK-927 at the 0.5% concentration appeared to be minimally effective in reducing intraocular pressure. A single topical dose of 1% MK-927 resulted in a significantly greater percent reduction in intraocular pressure for up to 6 hours when compared with treatment with placebo. Similarly, a single dose of 2% MK-927 significantly lowered intraocular pressure for 8 hours compared with treatment with placebo. The pressure reduction from baseline measured 23.7% and 11.3% at 8 hours after instillation of a single drop of 2% MK-927. The medication was well tolerated and appeared to lower intraocular pressure in a dose-dependent fashion. © 1990, American Medical Association. All rights reserved.
引用
收藏
页码:65 / 68
页数:4
相关论文
共 19 条
[11]  
MAREN T H, 1988, Investigative Ophthalmology and Visual Science, V29, P16
[12]  
MAREN TH, 1971, ARCH OPHTHALMOL-CHIC, V85, P1
[13]  
MAREN TH, 1963, J PHARMACOL EXP THER, V139, P140
[14]  
MAREN TH, 1977, INVEST OPHTH VIS SCI, V16, P730
[15]  
MICHELSON S R, 1989, Investigative Ophthalmology and Visual Science, V30, P24
[16]  
PONTICELLO GS, 1988, 3RD CHEM C N AM MED
[17]  
SUGRUE M F, 1988, Investigative Ophthalmology and Visual Science, V29, P81
[18]  
TUULONEN A, 1989, Investigative Ophthalmology and Visual Science, V30, P24
[19]  
WANG R-F, 1988, Investigative Ophthalmology and Visual Science, V29, P16